{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:35Z","timestamp":1787841335124,"version":"build-2784847793"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T00:00:00Z","timestamp":1583884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Hematopoietic cell transplant (HCT) can cure both children and adults with sickle cell disease. Outcomes have historically been poor for the vast majority of patients who lack a matched sibling donor. However, the development of haploidentical HCT (haplo-HCT) with high doses of posttransplant cyclophosphamide (PTCy) has allowed for curative long-term potential with favorable transplant-related outcomes, though this has not obviated the potential for graft rejection from human leukocyte antigen mismatch and repeated red blood cell transfusions. Accordingly, multiple strategies have been developed to improve outcomes, the majority of which are based on the Johns Hopkins platform from 2012. Presently, we aim to discuss results from pertinent studies and compare outcomes with the two most recent approaches involving either thiotepa plus 200-cGy total body irradiation or 400-cGy total body irradiation. Direct comparisons are required to determine the optimized curative potential. Transplant-eligible patients must be referred to tertiary medical centers for consideration of haplo-HCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.01.002","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T16:15:35Z","timestamp":1584029735000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease"],"prefix":"10.4103","volume":"13","author":[{"given":"Dilan A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeseye M.","family":"Akinsete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josu de la","family":"Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola A.","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241211","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"R2-9-20241211","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-9-20241211","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"R4-9-20241211","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"key":"R5-9-20241211","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","article-title":"Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain","volume":"28","author":"Hebbel","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"R6-9-20241211","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2016-01-694562","article-title":"Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia","volume":"127","author":"Kassim","year":"2016","journal-title":"Blood"},{"key":"R7-9-20241211","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N Engl J Med"},{"key":"R8-9-20241211","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N Engl J Med"},{"key":"R9-9-20241211","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"R10-9-20241211","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of lglutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-9-20241211","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"key":"R12-9-20241211","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-9-20241211","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"R14-9-20241211","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/bloodadvances.2017007708","article-title":"The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"key":"R15-9-20241211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"R16-9-20241211","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bmt.1703887","article-title":"Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies","volume":"31","author":"Krishnamurti","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R17-9-20241211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CCO.0b013e328324ba04","article-title":"Blood and marrow transplantation for sickle cell disease: overcoming barriers to success","volume":"21","author":"Bolanos-Meade","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"R18-9-20241211","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.seminhematol.2018.04.013","article-title":"When there is no match, the game is not over: alternative donor options for hematopoietic stem cell transplantation in sickle cell disease","volume":"55","author":"Joseph","year":"2018","journal-title":"Semin Hematol"},{"key":"R19-9-20241211","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.hemonc.2017.05.008","article-title":"Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape","volume":"10","author":"Kassim","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R20-9-20241211","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood"},{"key":"R21-9-20241211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"R22-9-20241211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R23-9-20241211","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"R24-9-20241211","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ FOXP3+ regulatory T cells are necessary for posttransplantation cyclophosphamide mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"R25-9-20241211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2008.203","article-title":"Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases","volume":"42","author":"Brodsky","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R26-9-20241211","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv"},{"key":"R27-9-20241211","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R28-9-20241211","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00277-017-3030-x","article-title":"Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease","volume":"96","author":"Wiebking","year":"2017","journal-title":"Ann Hematol"},{"key":"R29-9-20241211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbmt.2017.08.039","article-title":"HLA Haploidentical stem cell transplant with pretransplant immunosuppression for patients with sickle cell disease","volume":"24","author":"Pawlowska","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-9-20241211","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplant with post-transplant cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative","volume":"25","author":"de la Fuente","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R31-9-20241211","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"key":"R32-9-20241211","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.bmt.1705622","article-title":"A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease","volume":"39","author":"Chakrabarti","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"R33-9-20241211","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"R34-9-20241211","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2013.01.016","article-title":"Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies","volume":"19","author":"Gladstone","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"R35-9-20241211","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"key":"R36-9-20241211","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17474086.2019.1642103","article-title":"T-cell deplete versus T-cell replete haploidentical hematopoietic stem cell transplantation for sickle cell disease: where are we?","volume":"12","author":"Patel","year":"2019","journal-title":"Exp Rev Hematol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838762030025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S165838762030025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.01.002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:15Z","timestamp":1787838615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.01.002"}},"subtitle":["An update"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.01.002","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}